Literature DB >> 8330440

Thyroxine replacement therapy and circulating lipid concentrations.

J A Franklyn1, J Daykin, J Betteridge, E A Hughes, R Holder, S R Jones, M C Sheppard.   

Abstract

OBJECTIVE: Hypothyroidism is a common disorder and while the association of overt hypothyroidism with hypercholesterolaemia is clear, the effect upon lipids of the minor abnormalities of thyroid function often found in those receiving T4 replacement therapy is unclear. The aim of the present studies was to define in those with hypothyroidism the effect upon circulating lipids of subtle changes in thyroid status, indicated by serum TSH values below or above the normal range.
DESIGN: (i) Prospective study of short-term T4 treatment of those with subclinical hypothyroidism. (ii) Cross-sectional study of long-term T4 treatment, comparing non-T4 treated controls and T4 treated patients with serum TSH values either below or within the normal range. PATIENTS: Short-term T4 therapy was examined in 11 post-menopausal females with subclinical hypothyroidism (high TSH, normal free T4) studied before therapy and 6 weeks after T4 at incremental doses (50, 100, 150 micrograms/day). Long-term T4 treatment for hypothyroidism was investigated in 105 females on therapy for at least 1 year compared with 105 controls matched for age and menopausal status. MEASUREMENTS: Fasting levels of total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol and HDL subfractions were determined in patients and controls.
RESULTS: (i) T4 treatment of subjects with subclinical hypothyroidism resulted in reductions in total and LDL cholesterol with increasing T4 dose (P < 0.001). Comparison of lipid results pretreatment with those when TSH was restored to normal revealed no significant difference in lipids; in contrast, comparison of lipids in those with normal TSH compared with the same subjects when TSH was suppressed revealed reductions in total and LDL cholesterol. (ii) Long-term T4 treatment was associated with a reduction in total and LDL cholesterol measurements in those over 55 years receiving suppressive doses of T4 but no significant difference in lipids in those with normal serum TSH compared with non-T4 treated controls.
CONCLUSION: Effects of T4 upon lipid measurements suggest that patients with subclinical hypothyroidism should receive replacement therapy. Doses of T4 which suppress TSH to below normal may have a more significant influence upon lipids than doses of T4 which restore TSH to the normal range.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8330440     DOI: 10.1111/j.1365-2265.1993.tb00339.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

Review 1.  Controversial aspects of thyroid disease.

Authors:  F W Hanna; J H Lazarus; M F Scanlon
Journal:  BMJ       Date:  1999-10-02

2.  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey.

Authors:  Christian Meier; Peter Trittibach; Merih Guglielmetti; Jean-Jacques Staub; Beat Müller
Journal:  BMJ       Date:  2003-02-08

3.  Hypothyroidism, thyroxine treatment, and the heart.

Authors:  M Gammage; J Franklyn
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

4.  Atrial fibrillation and the pituitary-thyroid axis: a re-evaluation.

Authors:  J C Forfar
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

Review 5.  Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?

Authors:  Matthew D Ettleson; Antonio C Bianco
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

6.  Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice.

Authors:  P De Whalley
Journal:  Br J Gen Pract       Date:  1995-02       Impact factor: 5.386

7.  Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: overt and subclinical hypothyroidism.

Authors:  M C Vantyghem; A Ghulam; C Hober; C Schoonberg; M D'Herbomez; A Racadot; A Boersma; J Lefebvre
Journal:  J Endocrinol Invest       Date:  1998-04       Impact factor: 4.256

Review 8.  Scope and limitations of iodothyronine deiodinases in hypothyroidism.

Authors:  Balázs Gereben; Elizabeth A McAninch; Miriam O Ribeiro; Antonio C Bianco
Journal:  Nat Rev Endocrinol       Date:  2015-09-29       Impact factor: 43.330

9.  Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease.

Authors:  Melpomeni Peppa; Grigoria Betsi; George Dimitriadis
Journal:  J Lipids       Date:  2011-07-18

10.  Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study.

Authors:  Massimo Giusti; Lorenzo Mortara; Roberta Degrandi; Francesca Cecoli; Michele Mussap; Guido Rodriguez; Diego Ferone; Francesco Minuto
Journal:  Thyroid Res       Date:  2008-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.